沙波什尼科维亚·迪瓦里卡塔 (Saposhnikovia divaricata) 根及其主要成分可缓解炎症并改变DSS诱发性结肠炎的肠道微生物多样性和组成
Saruul Erdenebileg1,2, Yang-Ju Son3, Myungsuk Kim4
1Smart Farm Research Center, Korea Institute of Science and Technology (KIST), Gangneung, South Korea.
Integrative medicine research
|November 29, 2023
概括
萨波什尼科维亚·迪瓦里卡塔 (Saposhnikovia divaricata,简称MESD) 的根提取物显示出对炎症性肠病 (IBD) 的抗炎作用. 在小鼠中,MESD降低了炎症性细胞因子,并改变了肠道微生物群的组成.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 萨波什尼科维亚 (Saposhnikovia divaricata) 根是一种具有抗炎功能的传统药物.
- 对炎症性肠病 (IBD) 缺乏临床验证.
- 这项研究调查了S. divaricata在改善IBD和改变肠道微生物群方面的潜力.
研究的目的:
- 评估Saposhnikovia divaricata根提取物 (MESD) 对IBD的抗炎作用.
- 在大肠炎模型中调查MESD对肠道微生物变化的影响.
- 为了确定MESD中负责抗炎活性的活性化合物.
主要方法:
- 使用的是Saposhnikovia divaricata根 (MESD) 的甲醇提取物.
- 采用了RAW 264.7巨细胞系和硫酸 (DSS) 诱导的大肠炎的小鼠模型.
- 进行了16S rRNA基因测序,以分析肠道微生物群的组成.
主要成果:
- 在体外,MESD降低了氧化和炎症性细胞因子.
- 在DSS诱导的大肠炎小鼠中,口服MESD的使用降低了结肠炎性细胞因子.
- MESD改变了肠道微生物群,抑制了Clostridium sensu stricto1并增强了特定的代谢途径. 鉴定出强效的抗炎化合物3'-O-乙hamaudol和3'-O-angeloylhamaudol. 这两种化合物具有很强的抗炎作用.
结论:
- MESD显示出作为IBD的天然治疗方法的潜力.
- 提取物有效降低炎症并调节肠道微生物群.
- 对MESD及其用于IBD治疗的活性化合物的进一步研究是有必要的.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182


